Clinical Trials Browser

INDUSTRY × Has results × Ipilimumab × Clear all

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Phase 2 Completed

378 enrolled 15 charts 1 FDA

Uveal Melanoma, Melanoma

NCT03036098 2026-03-06

CheckMate901

Phase 3 Active not recruiting

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Phase 1/2 Completed

281 enrolled 44 charts

Melanoma, Neoplasms

NCT03143153 2026-02-17

CheckMate 648

Phase 3 Completed

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT01658878 2025-12-24

CheckMate040

Phase 1/2 Completed

657 enrolled 57 charts 3 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT02985957 2025-12-22

CheckMate 650

Phase 2 Completed

351 enrolled 43 charts

Prostatic Neoplasms

NCT03215706 2025-12-17

CheckMate 9LA

Phase 3 Completed

719 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03377361 2025-12-03

CheckMate 9N9

Phase 1/2 Completed

325 enrolled 31 charts

Gastrointestinal

Colorectal Neoplasms

NCT03369223 2025-11-18

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Phase 1/2 Completed

356 enrolled 43 charts

Advanced Cancer

NCT02060188 2025-11-06

CheckMate142

Phase 2 Completed

385 enrolled 17 charts 2 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Phase 1/2 Completed

320 enrolled 35 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT04008030 2025-10-03

CheckMate 8HW

Phase 3 Active not recruiting

839 enrolled 22 charts 1 FDA

Gastrointestinal

Colorectal Neoplasms

NCT05407675 2025-10-03

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

68 enrolled 27 charts

Neoplasms

NCT03195478 2025-09-15

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

Phase 1/2 Completed

37 enrolled 32 charts

Other solid neoplasm

Solid Tumor

NCT03937219 2025-09-10

COSMIC-313

Phase 3 Active not recruiting

855 enrolled 12 charts

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Phase 1/2 Completed

145 enrolled 47 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02872116 2025-08-07

CheckMate649

Phase 3 Completed

2,031 enrolled 19 charts 1 FDA

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05116202 2025-07-18

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

Phase 1/2 Completed

110 enrolled 27 charts

Melanoma

NCT04513522 2025-07-11

CheckMate 7C9

Phase 4 Completed

101 enrolled 12 charts

Kidney Neoplasms

NCT02231749 2025-06-26

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Phase 3 Completed

1,390 enrolled 18 charts 1 FDA

Carcinoma, Renal Cell

NCT03739710 2025-06-15

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

175 enrolled 5 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03141177 2025-06-06

CheckMate 9ER

Phase 3 Active not recruiting

701 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT02259231 2025-06-04

RTA 408 Capsules in Patients With Melanoma - REVEAL

Phase 1/2 Completed

41 enrolled 15 charts

Melanoma, Neoplasm Metastasis

NCT06790303 2025-06-04

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2

Phase 2 Terminated

8 enrolled 11 charts

Neoplasms

NCT01844505 2025-05-21

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Phase 3 Completed

945 enrolled 19 charts

Melanoma

NCT02388906 2025-04-24

CheckMate 238

Phase 3 Completed

906 enrolled 16 charts 1 FDA

Melanoma

NCT02913313 2025-04-20

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Phase 1/2 Completed

101 enrolled 34 charts

Other solid neoplasm

Broad Solid Tumor

NCT03058289 2025-02-27

IT-01

Phase 1/2 Completed

111 enrolled 21 charts

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT04382664 2025-01-14

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Phase 2 Completed

156 enrolled 11 charts

Melanoma

NCT01928394 2024-12-27

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

1,163 enrolled 33 charts 1 FDA

Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT03138512 2024-12-18

CheckMate 914

Phase 3 Completed

1,641 enrolled 21 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT04340193 2024-11-26

CheckMate 74W

Phase 3 Completed

26 enrolled 15 charts

Gastrointestinal

Liver Neoplasms

NCT03668119 2024-08-28

CheckMate 848

Phase 2 Completed

212 enrolled 21 charts

Pan Tumor

NCT02899299 2024-05-21

CheckMate743

Phase 3 Completed

605 enrolled 17 charts 2 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT03001882 2024-05-20

CheckMate 592

Phase 2 Completed

230 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT03711188 2024-04-29

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

Phase 2 Completed

16 enrolled 14 charts

Melanoma

NCT01621490 2024-04-23

PD-1

Phase 1 Completed

170 enrolled 34 charts

Melanoma

NCT02723006 2024-03-05

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

Phase 1 Terminated

22 enrolled 14 charts

Melanoma

NCT05005273 2024-02-28

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

1 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT01856023 2023-12-05

PROCLIVITY02

Phase 4 Terminated

29 enrolled 9 charts

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT04894994 2023-12-05

FLX475 in Combination With Ipilimumab in Advanced Melanoma

Phase 2 Terminated

6 enrolled 10 charts

Neoplasms

NCT02864251 2023-09-28

CheckMate722

Phase 3 Completed

367 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT03302234 2023-09-26

KEYNOTE-598

Phase 3 Completed

568 enrolled 20 charts

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02741570 2023-09-21

CheckMate 651

Phase 3 Completed

947 enrolled 19 charts

Head and Neck Neoplasms

NCT02904226 2023-07-03

ICONIC

Phase 1/2 Completed

242 enrolled 29 charts

Neoplasms

NCT02869789 2023-06-15

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Phase 4 Completed

1,041 enrolled 18 charts

Lung Neoplasms

NCT02935634 2023-06-09

FRACTION-GC

Phase 2 Completed

190 enrolled 25 charts

Gastrointestinal

Advanced Gastric Cancer

NCT02823574 2023-05-03

CheckMate 714

Phase 2 Completed

425 enrolled 46 charts

Head and Neck Neoplasms